Decision-ready evidence, accelerated.

We generate comparative evidence for market access.

We combine deep methodological expertise with purpose-built workflows to generate the comparative evidence your asset needs, in weeks instead of months.

Your drug has never been compared directly against the alternative.

Your pivotal evidence comes from a single-arm trial. Or you have randomised data but not against standard of care or the drug your asset is competing with.

HTA bodies, payers, and clinical teams all want the same answer: how does your drug compare to what patients already receive?

That answer must come from evidence outside your trial. And it has to hold up to external scrutiny.

Evidax in numbers

20 days
Integrated Evidence Plan
14 days
Systematic review and meta-analysis
10 days
Indirect treatment comparison
15 years
Leading clinical research programmes

What we do

When your asset needs comparative data from outside a pivotal trial, we do two things exceptionally well: evidence strategy and evidence generation.

Evidence strategy

Evidence gap analysis

We map exactly what evidence you have, what is missing, and what each key stakeholder needs to see.

Integrated evidence plans

We build one multi-purpose plan that serves regulators, HTA bodies, payers, and clinicians simultaneously.

Evidence generation

Systematic reviews and meta-analyses

We synthesise every piece of published evidence on your question, and deliver the full pooled analysis, aligned with PRISMA and Cochrane guidance.

Comparative evidence

We compare your drug against the alternative using summary results published from other trials or patient-level data from real-world data sources.

More on what we do

Evidax is built differently

Working with a conventional firm

Working with a conventional firm usually goes like this: You are charged separately for every piece of work. Evidence generation takes several months. And the analysis is run by someone who has never developed an asset of their own.

Working with Evidax

Evidax is relentlessly outcome-driven; we agree the outcome first and work with you until it is delivered, with no extra charges along the way. We generate evidence in weeks rather than months, using workflows we built ourselves. And every analysis is run by a senior methodologist who has led major research programmes and developed their own asset.

More on our guarantee

How Evidax works

Contact us

Your streamlined evidence plan, live and in one place

The Evidax Workspace keeps your whole team aligned as the plan evolves and new evidence is generated.

See how the plan is built

The Evidax Workspace showing an integrated evidence plan: an evidence-stakeholder map, the six IEP Method steps and the evidence-generation workstreams.
Illustrative example.

Leadership team

Dr Sam Orange, Founder and Chief Scientific Officer at Evidax.

Dr Sam Orange

Founder & Chief Scientific Officer

Professor Ian Hickson, Senior Scientific Adviser in Drug Discovery at Evidax.

Professor Ian Hickson

Senior Scientific Adviser: Drug discovery

Dr Tom Maden-Wilkinson, Senior Scientific Advisor in Biotech Strategy at Evidax.

Dr Tom Maden-Wilkinson

Senior Scientific Advisor: Biotech strategy

Professor James Wason

Professor James Wason

Senior Scientific Advisor: Biostatistics

Ben Porter

Ben Porter

Senior Scientific Advisor: RWE and evidence synthesis

More about the team

If your pivotal trial gets you approval but not reimbursement, we should talk.